We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.85B
AUM Growth
-$933M
Cap. Flow
-$365M
Cap. Flow %
-4.65%
Top 10 Hldgs %
37.02%
Holding
151
New
11
Increased
33
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$137M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$91.8M
3
AET
Aetna Inc
AET
+$82.5M
4
HUM icon
Humana
HUM
+$78.7M
5
MRK icon
Merck
MRK
+$68M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$146M
2
MOH icon
Molina Healthcare
MOH
+$117M
3
ESRX
Express Scripts Holding Company
ESRX
+$102M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$89.8M
5
ABBV icon
AbbVie
ABBV
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.02%
2 Financials 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
51
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$44.3M 0.56%
396,600
+360,400
+996% +$43.4M
COO icon
52
Cooper Companies
COO
$14.2B
$43.8M 0.56%
1,000,400
– –
JAZZ icon
53
Jazz Pharmaceuticals
JAZZ
$16.1B
$40.5M 0.52%
371,400
+124,500
+50% +$13.9M
SYK icon
54
Stryker
SYK
$135B
$37.9M 0.48%
316,300
+104,300
+49% +$12M
NTLA icon
55
Intellia Therapeutics
NTLA
$1.48B
$34.9M 0.44%
2,662,180
– –
RNAC icon
56
Cartesian Therapeutics
RNAC
$221M
$31.6M 0.4%
61,427
– –
OTIC
57
DELISTED
Otonomy, Inc.
OTIC
$29.4M 0.37%
1,850,094
– –
VRAY
58
DELISTED
ViewRay, Inc.
VRAY
$28.6M 0.36%
9,127,990
– –
ONC
59
BeOne Medicines Ltd
ONC
$34B
$27.4M 0.35%
+903,700
New +$28.4M
MOH icon
60
Molina Healthcare
MOH
$10.6B
$26.9M 0.34%
496,200
-2,138,500
-81% -$117M
CHRS icon
61
Coherus Oncology
CHRS
$217M
$23.9M 0.3%
850,100
+178,500
+27% +$5M
IOVA icon
62
Iovance Biotherapeutics
IOVA
$2.02B
$23.5M 0.3%
3,382,900
– –
DMTX
63
DELISTED
Dimension Therapeutics, Inc
DMTX
$23.5M 0.3%
5,397,698
– –
ILMN icon
64
Illumina
ILMN
$29.1B
$23.3M 0.3%
187,302
-322,072
-63% -$43.4M
TEVA icon
65
Teva Pharmaceuticals
TEVA
$39.9B
$22.3M 0.28%
614,500
-1,216,900
-66% -$48.6M
XNCR icon
66
Xencor
XNCR
$1.44B
$22.1M 0.28%
840,237
+95,715
+13% +$2.3M
LUMO
67
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$20.5M 0.26%
221,300
+5,933
+3% +$669K
HUM icon
68
CALL
Humana
HUM
$43.8B
$20.4M 0.26%
+100,000
New +$19.1M
EHTH icon
69
eHealth
EHTH
$42.2M
$19.4M 0.25%
1,820,000
+5,000
+0.3% +$51K
LKFT
70
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$18.2M 0.23%
283,500
-174,400
-38% -$10.7M
BLUE
71
DELISTED
bluebird bio
BLUE
$17.5M 0.22%
21,909
-69,635
-76% -$55.3M
ASMB icon
72
Assembly Biosciences
ASMB
$497M
$17M 0.22%
116,425
– –
SVA
73
DELISTED
Sinovac Biotech, Ltd
SVA
$15.7M 0.2%
2,667,500
– –
NTRA icon
74
Natera
NTRA
$35.7B
$14.9M 0.19%
1,276,190
– –
IMMU
75
DELISTED
Immunomedics Inc
IMMU
$14M 0.18%
3,802,000
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2016 Portfolio in Review

As of Q4 2016, OrbiMed held 151 positions worth $7.85B, down 11% from $8.78B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $365M in Q4 2016, closing 20 positions and reducing 26 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Elevance Health worth $147M.

  • OrbiMed's largest Q4 2016 buy was Elevance Health: 1,021,600 shares worth $147M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q4 2016, an estimated $91.8M increase.
  • OrbiMed's biggest Q4 2016 reduction was Molina Healthcare, cutting an estimated $117M.
  • OrbiMed fully exited Wellcare Health Plans, Inc. in Q4 2016, selling an estimated $146M.
  • OrbiMed's ten largest holdings make up 37% of its $7.85B portfolio in Q4 2016.
  • OrbiMed opened 11 new positions and closed 20 in Q4 2016.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $7.85B.

Based on OrbiMed's 13F filing for Q4 2016, filed 14 Feb 2017.